AI
| Followers | 843 |
| Posts | 122806 |
| Boards Moderated | 10 |
| Alias Born | 09/05/2002 |
Monday, July 09, 2007 7:52:20 AM
>Another problem is that Kamada may not have enough of the active pharmaceutical ingredient (API) for inhalable API to treat all cystic fibrosis patients.<
Not enough API to make API? That sounds like circular reasoning
On a more serious note…
>…API will be approved for cystic fibrosis even before it is approved for the treatment of congenital emphysema. Approval for treating both diseases is expected before 2009.<
It takes chutzpah to display such confidence in an indication (CF) where prior attempts to use AAT failed (#msg-21040079). Could this be a case where the Hebrew to English translation came out wrong?
Not enough API to make API? That sounds like circular reasoning
On a more serious note…
>…API will be approved for cystic fibrosis even before it is approved for the treatment of congenital emphysema. Approval for treating both diseases is expected before 2009.<
It takes chutzpah to display such confidence in an indication (CF) where prior attempts to use AAT failed (#msg-21040079). Could this be a case where the Hebrew to English translation came out wrong?
“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”
Discover What Traders Are Watching
Explore small cap ideas before they hit the headlines.
